Global Blood Therapeutics (NASDAQ:GBT) Lowered to Equal Weight at Wells Fargo & Company
Global Blood Therapeutics (NASDAQ:GBT) Lowered to Equal Weight at Wells Fargo & Company
Wells Fargo & Company downgraded shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) from an overweight rating to an equal weight rating in a report published on Tuesday, The Fly reports. The firm currently has $68.50 price target on the stock, up from their prior price target of $66.00.
据The Fly报道,在周二发布的一份报告中,富国银行将全球血液治疗公司(纳斯达克:GET-GET)的股票评级从增持下调至持平。该公司目前对该股的目标价为68.50美元,高于此前66.00美元的目标价。
A number of other research firms have also recently commented on GBT. Canaccord Genuity Group upgraded Global Blood Therapeutics from a hold rating to a buy rating and upped their price target for the stock from $40.00 to $72.00 in a research note on Monday. Stifel Nicolaus reiterated a hold rating on shares of Global Blood Therapeutics in a research note on Monday. JPMorgan Chase & Co. reduced their price objective on Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating on the stock in a research note on Tuesday, June 28th. William Blair cut Global Blood Therapeutics from an outperform rating to a market perform rating in a research note on Monday. Finally, Cowen cut Global Blood Therapeutics to a market perform rating and increased their price objective for the company from $67.00 to $68.50 in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Global Blood Therapeutics currently has an average rating of Hold and a consensus target price of $65.04.
其他一些研究公司最近也对GBT发表了评论。周一,Canaccel Genuity Group在一份研究报告中将全球血液治疗公司的评级从持有评级上调为买入评级,并将该股目标价从40.00美元上调至72.00美元。Stifel Nicolaus在周一的一份研究报告中重申了对全球血液治疗公司股票的持有评级。摩根大通在6月28日星期二的一份研究报告中将全球血液治疗公司的目标价从39.00美元下调至36.00美元,并对该股设定了中性评级。威廉·布莱尔周一在一份研究报告中将全球血液治疗公司的评级从表现优于市场下调至市场表现。最后,考恩在周二的一份研究报告中将全球血液治疗公司下调至市场表现评级,并将该公司的目标价从67.00美元上调至68.50美元。9名研究分析师对该股的评级为持有,7名分析师对该股的评级为买入。根据MarketBeat的数据,全球血液治疗公司目前的平均评级为持有,共识目标价为65.04美元。
Global Blood Therapeutics Stock Down 0.0 %
全球血液治疗类股下跌0.0%
NASDAQ:GBT opened at $66.59 on Tuesday. The company has a quick ratio of 7.74, a current ratio of 8.52 and a debt-to-equity ratio of 4.34. The stock's fifty day moving average is $32.87 and its two-hundred day moving average is $31.36. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -13.67 and a beta of 0.83.
纳斯达克:绿色壁垒周二开盘报66.59美元。该公司的速动比率为7.74,流动比率为8.52,债务权益比率为4.34。该股的50日移动均线切入位为32.87美元,200日移动均线切入位为31.36美元。全球血液治疗公司的52周低点为21.65美元,52周高点为73.02美元。该股市值为43.3亿美元,市盈率为-13.67倍,贝塔系数为0.83。
Insider Activity at Global Blood Therapeutics
全球血液治疗公司的内部活动
In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the firm's stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the transaction, the director now owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.90% of the stock is currently owned by corporate insiders.
在全球血液治疗公司的其他新闻中,董事菲利普·A·皮佐在一笔日期为6月21日(星期二)的交易中出售了1,260股该公司的股票。该股以27.25美元的平均价格出售,总成交金额为34,335.00美元。交易完成后,董事现在持有该公司9,112股股票,价值248,302美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站访问。4.90%的股份目前由企业内部人士持有。
Hedge Funds Weigh In On Global Blood Therapeutics
对冲基金参与全球血液治疗
A number of hedge funds and other institutional investors have recently made changes to their positions in GBT. Allspring Global Investments Holdings LLC purchased a new position in shares of Global Blood Therapeutics during the fourth quarter worth about $1,092,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Global Blood Therapeutics by 18.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,871 shares of the company's stock worth $1,343,000 after buying an additional 7,099 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Global Blood Therapeutics in the fourth quarter valued at about $332,000. DekaBank Deutsche Girozentrale lifted its position in Global Blood Therapeutics by 2.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 22,050 shares of the company's stock valued at $659,000 after purchasing an additional 600 shares during the period. Finally, Banque Pictet & Cie SA acquired a new stake in Global Blood Therapeutics in the fourth quarter valued at about $1,293,000.
一些对冲基金和其他机构投资者最近改变了他们在GBT的头寸。AllSpring Global Investments Holdings LLC在第四季度购买了全球血液治疗公司的新头寸,价值约1,092,000美元。第四季度,苏黎世广东银行持有的全球血液治疗公司股票增加了18.3%。苏黎世广东银行现在持有45,871股该公司股票,价值1,343,000美元,在上个季度又购买了7,099股。奥本海默公司在第四季度收购了全球血液治疗公司的新股份,价值约33.2万美元。德意志银行第四季度将其在全球血液治疗公司的地位提高了2.8%。DekaBank Deutsche Girozentrale在此期间又购买了600股,现在拥有22,050股该公司股票,价值65.9万美元。最后,Banque Pictet&Cie SA在第四季度收购了全球血液治疗公司的新股份,价值约1,293,000美元。
Global Blood Therapeutics Company Profile
全球血液治疗公司简介
(Get Rating)
(获取评级)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治疗公司是一家生物制药公司,致力于发现、开发和提供针对服务不足的镰状细胞疾病(SCD)患者群体的治疗方法。该公司提供Oxbryta片剂,这是一种治疗SCD的口服药物,每天一次。它还在第二阶段对青少年和儿童SCD患者的临床试验中评估了单剂和多剂Oxbryta的安全性和药代动力学。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免费获取StockNews.com关于全球血液治疗(GBT)的研究报告
- 3M、霍尼韦尔、通用电气在季度报告后收购吗?
- CVS和Walgreens展示为什么投资目标很重要
- 索菲金融股票终于准备好为投资者买单了吗?
- 这只国防股票的基本面和技术面都看涨
- 美敦力和直觉外科公司准备实现大增长吗?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对全球血液治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。